Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAZZLE: KSI-301 vs Aflibercept in Wet AMD
NCT04049266Phase 3Terminated
- Sponsor
- Kodiak Sciences
- Start
- Oct 2019
- Primary completion
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of tarcocimab tedromer in age-related macular degeneration (AMD), sponsored by Kodiak Sciences. Started Oct 2019; status: terminated.
02
Drugs
tarcocimab tedromer
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT04049266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04049266.